Payment overview · 2025
General Payments
$310.43
19 reported records · 8 companies
Healthcare provider profile · identity verified
Judy Hacker, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MANCHESTER, KY · NPI 1770962961
Verified facts
What the public records show
CMS Open Payments records show Judy Hacker, APRN received $310.43 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.00 | 50.9% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $32.87 | 10.6% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.61 | 7.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.95 | 7.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.13 | 6.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.61 | 6.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.92 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.34 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $310.43 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.84 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $33.53 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.53 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 394 | 75 |
| Lisinopril | Lisinopril | 376 | 56 |
| Gabapentin | Gabapentin | 357 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 48 |
| Omeprazole | Omeprazole | 294 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 35 |
| Metformin Hcl | Metformin Hcl | 190 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 36 |
| Montelukast Sodium | Montelukast Sodium | 181 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 26 |
| Clonazepam | Clonazepam | 144 | 25 |
| Simvastatin | Simvastatin | 118 | 17 |
| Furosemide | Furosemide | 108 | 21 |
| Ozempic | Semaglutide | 105 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 16 |
| Januvia | Sitagliptin Phosphate | 96 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 95 | 14 |
| Ezetimibe | Ezetimibe | 91 | 13 |
| Meloxicam | Meloxicam | 88 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 15 |
| Ibuprofen | Ibuprofen | 80 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 11 |
| Famotidine | Famotidine | 77 | 19 |
| Fenofibrate | Fenofibrate | 77 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 14 |
| Amoxicillin | Amoxicillin | 70 | 44 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 70 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 69 | 13 |
| Sertraline Hcl | Sertraline Hcl | 67 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 17 |
| Buspirone Hcl | Buspirone Hcl | 66 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 16 |
| Cefdinir | Cefdinir | 65 | 51 |
| Alprazolam | Alprazolam | 62 | 14 |
| Ondansetron Odt | Ondansetron | 62 | 11 |
| Eliquis | Apixaban | 60 | 11 |
| Allopurinol | Allopurinol | 58 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Prednisone | Prednisone | 51 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Losartan Potassium | Losartan Potassium | 49 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 32 |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 12 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 14 |
| Diazepam | Diazepam | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 15 |
| Colchicine | Colchicine | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trandolapril | Trandolapril | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $310.43 · 19 records | ABBVIE INC. | ACCRUFER, CAPLYTA, CREON, Cologuard Collection Kit, IBSRELA, LINZESS, QULIPTA, SPRAVATO, UBRELVY, VRAYLAR, XIFAXAN, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error